Chargement en cours...
Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma
In 2009, the FDA approved bevacizumab for the treatment of adult patients diagnosed with recurrent glioblastoma. However, the poor permeability of the macromolecules across the blood–brain barrier, determined by multifactorial anatomical and physiological milieu, restricts the clinical therapeutic e...
Enregistré dans:
| Publié dans: | AMB Express |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6794332/ https://ncbi.nlm.nih.gov/pubmed/31617104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13568-019-0869-3 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|